656 related articles for article (PubMed ID: 18462867)
21. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
22. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cellular radiation responses by histone deacetylase inhibitors.
Karagiannis TC; El-Osta A
Oncogene; 2006 Jun; 25(28):3885-93. PubMed ID: 16462761
[TBL] [Abstract][Full Text] [Related]
24. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
25. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
Johnstone RW
Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
28. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Acharya MR; Sparreboom A; Venitz J; Figg WD
Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors: multifunctional anticancer agents.
Liu T; Kuljaca S; Tee A; Marshall GM
Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
31. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
33. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
35. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors in myelodysplastic syndrome.
Bhalla K; List A
Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
[TBL] [Abstract][Full Text] [Related]
37. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Dzieran J; Beck JF; Sonnemann J
Cancer Sci; 2008 Aug; 99(8):1685-92. PubMed ID: 18754884
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
39. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
[TBL] [Abstract][Full Text] [Related]
40. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]